We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




AI-Powered Surgical Planning Tool Improves Pre-Op Planning

By HospiMedica International staff writers
Posted on 26 Mar 2025

Physicians have traditionally relied on flat, 2D images to plan medical procedures. More...

Now, a new application now leverages imaging technologies such as CT scans and MRIs to convert these static 2D images into dynamic 3D models in real-time, using AI and thousands of radiologic images. The goal is to assist physicians in making more informed clinical decisions, allowing them to preserve as much tissue as possible and improve tumor margins.

Olympus Corp. (Tokyo, Japan), in partnership with software firm, Ziosoft (Newark, CA, USA), has introduced its first AI-powered clinical decision tool. This tool integrates advanced imaging analytics and machine learning, giving surgeons greater control over their preoperative planning. The initial three applications launched under the Ziosoft Revoras platform aim to transform liver, lung, and kidney surgeries. The first application, designed for thoracic surgery, converts 2D CT/MRI images into detailed 3D models, helping with lung cancer treatment planning and reducing the need for invasive procedures. The second application targets liver surgeries, assisting general and hepatobiliary surgeons in visualizing liver anatomy, practicing procedures beforehand, and planning liver-sparing surgeries by mapping out blood vessels. The third application focuses on urologic surgery, supporting minimally invasive nephrectomies by accurately evaluating the size, shape, and location of tumors, cysts, or other abnormalities.

The introduction of 3D procedure modeling not only enhances surgical precision but also serves as a valuable educational tool for surgical fellows, guiding newer surgeons through unfamiliar tasks and workflows. This development is in line with Olympus' commitment to improving surgical outcomes through AI-powered clinical decision support. The launch of these applications is part of a broader series of innovations under the "Seeing the Invisible" initiative, which aims to make surgeries safer, more efficient, and consistently successful. Additionally, this surgical planning tool is being introduced alongside Olympus' Intelligent Endoscopy Ecosystem, which integrates AI technologies with hardware, software, services, and data to enhance clinical decision-making and optimize workflows in gastrointestinal care.

"Olympus has a proud legacy in medical technology, particularly as a pioneer in endoscopy. We are excited to partner with Ziosoft, which has its own long history of developing AI software to help physicians make more accurate diagnostic and treatment decisions during procedures," said Darryl Rock, Vice President, Business Unit Leader, Surgical Solutions. "This collaboration represents a significant step forward in Olympus's mission to bring innovative, AI-enabled solutions to the healthcare industry."

"Ziosoft is committed to improving patient outcomes, and we are pleased to collaborate with Olympus to equip clinicians with greater diagnostic capabilities through advanced visualization," said Rajeev Taitriya, Vice President, Business Development and Marketing, Ziosoft. "By combining our expertise in AI-driven imaging with Olympus' leadership in minimally invasive treatment solutions, we can help enhance surgical precision and streamline workflows, ultimately improving patient care. With the rise of lung cancer screening, more patients are undergoing complex segmentectomies, which Ziosoft's REVORAS platform can support by enabling rapid pre-operative planning, allowing thoracic surgeons to make critical surgical decisions in minutes, helping to optimize outcomes and advance the standard of care."


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.